Cilostazol increases patency and reduces adverse outcomes in percutaneous femoropopliteal revascularisation: A meta-analysis of randomised controlled trials

Open Heart

Volumn 1, Issue 1, 2014, Pages

  Benjo, Alexandre M ^a   Garcia, Daniel C ^b   Jenkins, J Stephen ^a   Cardoso, Rhanderson M N ^b   Molina, Taina P ^c   El Hayek, Georges E ^d   Nadkarni, Girish N ^e   Aziz, Emad F ^d   Dinicolantonio, James J ^f   Collins, Tyrone ^a  

^a OCHSNER MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c Centro Universitario Luziadas School of Medicine   (Brazil)

^d ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAZOL;

ADVERSE OUTCOME; AMPUTATION; ARTICLE; DEATH; ENDOVASCULAR SURGERY; FOLLOW UP; HUMAN; INTERMITTENT CLAUDICATION; META ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS FEMOROPOPLITEAL REVASCULARISATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTENOSIS; REVASCULARIZATION; RISK ASSESSMENT; SYSTEMATIC REVIEW; VASCULAR PATENCY;

EID: 84984649200     PISSN: None     EISSN: 20533624     Source Type: Journal    
DOI: 10.1136/openhrt-2014-000154     Document Type: Article

References (34)

1. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-6.
2. Tattersall MC, Johnson HM, Mason PJ. Contemporary and optimal medical management of peripheral arterial disease. Surg Clin North Am 2013;93:761-78, vii.
3. Zeller T. Current state of endovascular treatment of femoro-popliteal artery disease. Vasc Med 2007;12:223-34.
4. Balzer JO, Thalhammer A, Khan V, et al. Angioplasty of the pelvic and femoral arteries in PAOD: results and review of the literature. Eur J Radiol 2010;75:48-56.
5. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 2007;33(Suppl 1):S1-75.
6. Rooke TW, Hirsch AT, Misra S, et al. American College of Cardiology Foundation; American Heart Association Task Force; Society for Cardiovascular Angiography and Interventions; Society of Interventional Radiology; Society for Vascular Medicine; Society for Vascular Surgery. ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline). Vasc Med 2011;16:452-76.
7. Tendera M, Aboyans V, Bartelink ML, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the task force on the diagnosis and treatment of peripheral artery diseases of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2851-906.
8. Thompson PD, Zimet R, Forbes WP, et al. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002;90:1314-19.
9. Squires H, Simpson E, Meng Y, et al. A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health Technol Assess 2011;15:1-210.
10. Inoue T, Kobayashi M, Uetsuka Y, et al. Pharmacoeconomic analysis of cilostazol for the secondary prevention of cerebral infarction. Circ J 2006;70:453-8.
11. Biondi-Zoccai GG, Testa L, Agostoni P. A practical algorithm for systematic reviews in cardiovascular medicine. Ital Heart J 2004;5:486-7.
12. Moher D, Liberati A, Tetzlaff J, et al; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.
13. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions version 5.1.0 (Updated March 2011). The Cochrane Collaboration, 2011.
14. Iida O, Nanto S, Uematsu M, et al. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. J Vasc Surg 2008;48:144-9.
15. Soga Y, Yokoi H, Kawasaki T, et al. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. J Am Coll Cardiol 2009;53:48-53.
16. Iida O, Yokoi H, Soga Y, et al. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. Circulation 2013;127:2307-15.
17. Minar E, Pokrajac B, Maca T, et al. Endovascular brachytherapy for prophylaxis of restenosis after femoropopliteal angioplasty: results of a prospective randomized study. Circulation 2000;102:2694-9.
18. Laird JR, Katzen BT, Scheinert D, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv 2010;3:267-76.
19. Duda SH, Pusich B, Richter G, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation 2002;106:1505-9.
20. Duda SH, Bosiers M, Lammer J, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther 2006;13:701-10.
21. Duda SH, Bosiers M, Lammer J, et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol 2005;16:331-8.
22. van Tongeren RB, van Sambeek MR, van Overhagen H, et al. Endovascular brachytherapy for the prevention of restenosis after femoropopliteal angioplasty. Results of the VARA Trial. J Cardiovasc Surg 2005;46:437-43.
23. Dake MD, Ansel GM, Jaff MR, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol 2013;61:2417-27.
24. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 2006;354:1879-88.
25. Biondi-Zoccai GG, Lotrionte M, Anselmino M, et al. Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am Heart J 2008;155:1081-9.
26. Park SW, Cha IH, Kim CH, et al. Improved patency of transjugular intrahepatic portosystemic shunt: the efficacy of cilostazol for the prevention of pseudointimal hyperplasia in swine TIPS models. Cardiovasc Intervent Radiol 2007;30:719-24.
27. Kudo FA, Kondo Y, Muto A, et al. Cilostazol suppresses neointimal hyperplasia in canine vein grafts. Surg Today 2009;39:128-32.
28. Min PK, Jung JH, Ko YG, et al. Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting: a quantative coronary angiography and volumetric intravascular ultrasound study. Circ J 2007;71:1685-90.
29. Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999;159:2041-50.
30. Dawson DL, Cutler BS, Meissner MH, et al. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998;98:678-86.
31. Money SR, Herd JA, Isaacsohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998;27:267-74; discussion 274-265.
32. Takahashi S, Oida K, Fujiwara R, et al. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol 1992;20:900-6.
33. Lammer J, Bosiers M, Zeller T, et al. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease. J Vasc Surg 2011;54:394-401.
34. Han Y, Li Y, Wang S, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J. 2009;157:733-9.